Superfoods Advisor

Adaptogens Explained: What the Research Says About Ashwagandha, Rhodiola, and Ginseng

By Superfoods Advisor Editors·July 4, 2026

Close-up of orange-red ashwagandha berries half-wrapped in papery husks

What are adaptogens? Herbs said to raise resistance to stress. How strong the clinical evidence is for ashwagandha, rhodiola, ginseng, maca and reishi.

Adaptogens are plants and fungi, such as ashwagandha (Withania somnifera), rhodiola (Rhodiola rosea) and Panax ginseng, that are said to increase the body’s non-specific resistance to stress and help normalize stress physiology. The clinical evidence is uneven: ashwagandha has several controlled trials, while other herbs sold as adaptogens rest mostly on animal models.

The term was coined by Soviet pharmacologist Nikolai Lazarev in 1947. His criteria were strict: a substance had to be safe, produce minimal side effects, and help normalize physiological functions regardless of the direction of the stressor. Brekhman and Dardymov later formalized these criteria in 1969 (Brekhman and Dardymov, 1969), and later Soviet-era and Scandinavian research gave the concept its scientific scaffolding.

What Makes a Compound an Adaptogen?

Researchers define a true adaptogen by three functional criteria: it must be non-toxic at normal doses, produce a non-specific stress-protective response, and normalize physiological parameters under stress. A 2010 review by Panossian and Wikman (Pharmaceuticals) (PubMed) linked the stress-protective activity of adaptogens, largely from animal and cell studies, to the HPA axis and to key stress mediators such as the chaperone HSP70, the kinase JNK1, cortisol, and nitric oxide. This definition excludes most stimulants, sedatives, and tonics, even though these are frequently co-marketed with adaptogens.

The HPA axis responds to perceived stress by releasing cortisol from the adrenal cortex. Chronic HPA over-activation is associated with impaired immune function, poor sleep, metabolic dysregulation, and cognitive fatigue. Adaptogens are proposed to restore HPA sensitivity rather than simply blunt or amplify the stress response. That mechanistic claim is plausible in animal models; human evidence is present but more limited in scope.

Does Ashwagandha (Withania somnifera) Actually Reduce Stress?

Ashwagandha (Withania somnifera) is an Ayurvedic root with the most consistent clinical evidence in the adaptogen category. The main compounds studied are withanolides, steroidal lactones proposed to act on HPA-axis signaling. The most-studied commercial extract is KSM-66, standardized to at least 5% withanolides. A 2022 meta-analysis of 12 RCTs (1,002 participants) found lower stress and anxiety scores with ashwagandha than placebo, though the authors rated the certainty of the evidence as low (Akhgarjand et al., 2022).

Mechanisms of Action

Withanolides are steroidal compounds, and one hypothesis is that they moderate glucocorticoid signaling; this has not been confirmed in humans. Preclinical data also point to GABAergic receptor modulation, which may explain the anxiolytic and sleep-promoting effects observed in human trials. Triethylene glycol, a non-withanolide compound in ashwagandha leaves, induced sleep in mice (Kaushik et al., 2017); whether it contributes to the effects of root extracts in humans is not established.

Most of these trials run 8 to 10 weeks and measure outcomes mainly at the end, so how quickly effects appear is not well established; the available data are more consistent with gradual change than with acute action.

Clinical Evidence for Stress and Cortisol

The 2012 KSM-66 RCT (Chandrasekhar et al., Indian Journal of Psychological Medicine) enrolled 64 adults with chronic stress and found a significantly larger fall in serum cortisol than with placebo (27.9% from baseline in the ashwagandha group) and significant improvements on all stress-assessment scales, including the Perceived Stress Scale, at 60 days. (PubMed, 2012)

A 2014 systematic review by Pratte and colleagues (Journal of Alternative and Complementary Medicine) identified five human trials of ashwagandha for anxiety or stress; all reported greater improvement than the comparator, mostly statistically significant, but every study had unclear or high risk of bias and the designs were too heterogeneous to pool. (PubMed, 2014)

Sleep quality is an under-discussed benefit with consistent signals. A 2019 randomized trial (Langade et al., Cureus) in 60 patients with insomnia and anxiety found that 300 mg of a full-spectrum root extract twice daily for 10 weeks shortened sleep onset latency and improved sleep efficiency, sleep quality, and anxiety scores versus placebo. (PubMed, 2019)

Evidence Summary: Ashwagandha

Verdict: Moderate-to-Strong

Multiple double-blind RCTs, many funded by extract manufacturers, report cortisol reduction, perceived stress improvement, and sleep quality benefits at 300-600 mg/day of standardized root extract. Pooled effects are large, but heterogeneity is high and the certainty of the evidence has been rated low. Gaps remain in longer-term safety data beyond 12 weeks and in head-to-head comparisons with standard-of-care treatments. Evidence is weakest for immune function, muscle recovery, and testosterone claims.

How Strong Is the Evidence for Rhodiola Rosea?

Rhodiola rosea is an arctic-alpine root with a distinct research profile from ashwagandha. Its marker compounds are rosavins and salidroside (commercial extracts are commonly standardized to 3% and 1%), and its primary documented benefit is reducing mental fatigue under acute stress. Unlike ashwagandha, rhodiola’s strongest evidence comes from short-duration, high-stress scenarios rather than chronic cortisol reduction. The European Medicines Agency’s herbal committee adopted a traditional-use monograph in 2012 for temporary relief of symptoms of stress such as fatigue, a status based on long-standing use rather than proven efficacy (EMA, Arctic root summary).

Mechanisms: Rosavins, Salidroside, and Monoamine Pathways

Rosavins are phenylpropanoid glycosides used as the reference marker that distinguishes Rhodiola rosea from related species. In vitro, root extracts inhibited monoamine oxidase (MAO) A and B (van Diermen et al., 2009). Salidroside, found in several Rhodiola species, activates AMPK pathways and upregulates heat shock proteins in preclinical studies, potentially supporting cellular stress resistance. The combined action of these two compound classes may explain rhodiola’s activating, fatigue-reducing quality, which differs from the calming profile of ashwagandha.

The authentic species distinction matters practically. An analysis of products sold in Europe found that about one fifth of those labelled R. rosea contained no rosavin and that adulteration with other Rhodiola species, such as R. crenulata, appeared commonplace (Booker et al., 2016). Since rosavins are the species-specific marker, products that do not state a rosavin content from verified R. rosea may not replicate the effects seen in clinical trials.

Clinical Evidence for Fatigue and Cognition

The 2003 Shevtsov trial in military cadets is among the larger single studies in the literature. A 2000 double-blind RCT by Spasov et al. (Phytomedicine) in foreign students taking a low repeated dose of SHR-5 for 20 days during exam season found improvements in physical fitness, mental fatigue, and neuro-motoric tests, though the authors judged the dose probably suboptimal. (PubMed, 2000) A 2011 systematic review by Hung and colleagues identified 11 placebo-controlled RCTs and concluded that R. rosea may benefit physical and mental performance, but noted a lack of independent replication of individual studies. (PubMed, 2011)

For exercise performance, evidence is preliminary. De Bock et al. (International Journal of Sport Nutrition and Exercise Metabolism, 2004) found that a single 200 mg dose of rhodiola extended time to exhaustion in 24 young healthy volunteers, but only slightly (16.8 to 17.2 minutes), and four weeks of daily intake did not change any measured outcome. (PubMed, 2004)

Evidence Summary: Rhodiola Rosea

Verdict: Moderate (for fatigue and cognition); Limited (for physical performance, mood, anxiety)

The acute fatigue signal is the most consistent in the literature, though a systematic review noted that individual trials lack independent replication (Hung et al., 2011). Evidence for chronic supplementation benefits, exercise performance, and mood disorders is preliminary and requires larger trials. Products standardized to rosavins and salidroside from authenticated R. rosea are the closest match to the extracts used in trials.

What Does Research Say About Panax Ginseng?

Ginseng (Panax ginseng) is among the oldest documented medicinal plants, with records in the Shennong Bencao Jing dating back approximately 2,000 years. More than 150 ginsenosides have been isolated across Panax species (Yang et al., 2020). These triterpenoid saponins are the primary bioactive class, operating through glucocorticoid receptor modulation, BDNF upregulation, and HPA axis attenuation in animal models. Human evidence is broad but thinner than ashwagandha’s cortisol evidence.

Ginsenosides and HPA Axis Modulation

Ginsenoside Rg1 activates the glucocorticoid receptor and promotes BDNF expression in hippocampal cells in preclinical models. Rb1, the most abundant ginsenoside in most Panax species, demonstrates sedative and neuroprotective properties. Red ginseng, produced by steaming white ginseng root, contains heat-modified ginsenosides such as Rg3 and Rh2; compound K, often discussed alongside them, is formed mainly by gut bacteria from ginsenosides after ingestion (Wang et al., 2011). Claims of superior bioavailability for red ginseng rest on limited human pharmacokinetic data. The HPA-modulating effect parallels ashwagandha and rhodiola at the mechanistic level, but the downstream clinical effects differ in character.

Clinical Evidence for Cognitive Function

Kennedy and colleagues (2001, Nutritional Neuroscience) found in a placebo-controlled, double-blind crossover trial in 20 healthy young adults that a single 400 mg dose of standardized P. ginseng extract (G115) improved “quality of memory” at every test point up to 6 hours, while the 200 mg and 600 mg doses slowed attention at later test times. (PubMed, 2001) The 2010 Geng Cochrane review could not pool its trials and found only suggestions of improvement in some aspects of cognition.

For fatigue, results are mixed. A 2013 RCT by Barton and colleagues (Journal of the National Cancer Institute) in 364 fatigued cancer survivors found that 2,000 mg/day of American ginseng (P. quinquefolius) did not significantly beat placebo at the 4-week primary endpoint (P = .07) but did improve cancer-related fatigue at 8 weeks (PubMed, 2013), making it the best-supported application for the fatigue indication. Evidence for fatigue reduction in healthy populations is weaker.

Evidence Summary: Panax Ginseng

Verdict: Limited-to-Moderate (cognitive function); Limited (physical performance); Moderate (cancer-related fatigue)

The most defensible clinical applications are modest cognitive support (particularly acute attention) and fatigue in clinical populations under disease stress. Evidence for healthy-population endurance enhancement does not hold up under rigorous trial conditions. Ginsenoside standardization varies widely across products, complicating cross-trial comparisons.

Is Maca Root a True Adaptogen?

Maca root (Lepidium meyenii) is a Peruvian Brassicaceae plant, not botanically related to Panax ginseng or classic HPA-axis adaptogens. It does not contain withanolides, ginsenosides, or rosavins. Its active compounds include glucosinolates and macamides, the latter structurally resembling endocannabinoids. Maca’s inclusion in “adaptogen” discussions is common in commercial contexts but technically imprecise. It does not demonstrably modulate the HPA axis.

What Maca Does Have Evidence For

The strongest signal in maca research is subjective libido. Beyond the Gonzales 2002 RCT, a 2008 crossover RCT by Brooks et al. (Menopause) in 14 postmenopausal women found that 3.5 g/day of maca for 6 weeks lowered sexual-dysfunction and psychological-symptom scores versus placebo without changing estradiol, FSH, LH, or SHBG. (PubMed, 2008) A separate 2008 pilot by Dording et al. (CNS Neuroscience & Therapeutics) in 20 outpatients with SSRI-induced sexual dysfunction compared two maca doses with no placebo arm; only the 3.0 g/day group improved. (PubMed, 2008) Neither the Gonzales nor the Brooks trial found hormonal changes, which suggests maca’s libido effects, where they exist, are non-androgenic.

Energy and endurance evidence is weaker. A small 2009 crossover RCT in trained male cyclists (n=8, Stone et al., Journal of Ethnopharmacology) found that 14 days of maca extract improved 40-km time-trial performance versus baseline but not versus placebo. (PubMed, 2009) No adequately powered endurance trials exist.

Evidence Summary: Maca Root

Verdict: Preliminary (libido); Insufficient (energy, endurance, HPA adaptation)

Maca has a plausible non-hormonal mechanism for libido and some positive trial signals in small samples. It should not be classified alongside ashwagandha or rhodiola as an HPA-axis adaptogen based on current evidence. Its nutritional value as a food is well established independently of its supplement claims.

Reishi as an Immune-Focused Adaptogen

Reishi mushroom (Ganoderma lingzhi, long sold and studied as G. lucidum) is categorized as an immune adaptogen rather than an HPA-axis adaptogen. Its bioactive compounds are triterpenes (ganoderic acids) and beta-glucan polysaccharides. These do not directly modulate cortisol or the stress response in the way withanolides or rosavins do. In laboratory studies, they modulate innate and adaptive immune function through Toll-like receptor activation and NK cell enhancement.

A 2016 Cochrane review of Ganoderma for cancer treatment (Jin et al.; five RCTs of generally unsatisfactory quality) found insufficient evidence to justify reishi as a first-line treatment, but noted possible improvements in tumour response and some immune markers when it was given alongside chemotherapy or radiotherapy. (PubMed, 2016) Its adaptogenic classification is best understood as immune homeostasis support rather than stress-axis modulation. The evidence base for reishi is smaller and more heterogeneous than for ashwagandha or rhodiola.

How Should You Choose and Use Adaptogens?

Selecting an adaptogen requires matching the compound’s evidence profile to your specific goal. Standardized extracts are not interchangeable with raw powders. The 2012 Chandrasekhar KSM-66 trial used root extract standardized to 5% withanolides at 300 mg twice daily. Replicating that result with a generic “ashwagandha powder” at unknown withanolide content is not guaranteed. Our ashwagandha supplements comparison ranks products on extract type, withanolide content and third-party testing, and the guide on how to take ashwagandha for sleep and anxiety covers timing and dose.

Standardized Extracts vs. Raw Powders

Standardization defines a guaranteed minimum level of the marker compound (withanolides, rosavins, ginsenosides). Without standardization, marker-compound content can vary substantially between batches, making consistent dosing difficult. For clinical applications, always confirm:

  • Ashwagandha: minimum 5% withanolides (KSM-66 or Sensoril are the best-documented extracts)
  • Rhodiola: 3% rosavins and 1% salidroside from authenticated Rhodiola rosea
  • Ginseng: a stated total-ginsenoside content (G115, the extract used in many cognition trials, is a standardized extract); specify Asian vs. American based on intended effect
  • Maca: no standardized marker is widely used; trials have used raw, gelatinized, and extracted forms

Dosing Ranges from Clinical Trials

AdaptogenStudied Dose RangeDuration in Trials
Ashwagandha (KSM-66)300-600 mg/day8-12 weeks
Rhodiola (SHR-5)340-680 mg/day (Darbinyan et al., 2007); single doses of 370-555 mgSingle dose to 6 weeks
Panax Ginseng (G115)200-600 mg single dosesMostly acute (hours)
Maca1,500-3,500 mg/day6-12 weeks

Cycling Adaptogens

Supplement guidance often suggests cycling adaptogens (several weeks on, followed by a break) to prevent tolerance. This practice lacks rigorous clinical validation in controlled trials. No published RCT has compared continuous vs. cycled protocols on outcomes. Cycling is a reasonable precautionary approach for most users, but it should not be presented as evidence-based protocol.

Safety and Drug Interactions

Adaptogens are generally well-tolerated at studied doses in healthy adults, but “well-tolerated” does not mean interaction-free. Safety data beyond 12 weeks of continuous use are limited for all adaptogens reviewed here. Most trials report adverse events as mild gastrointestinal symptoms.

Ashwagandha

Liver injury is rare but documented in case series. Five cases from Iceland and the US Drug-Induced Liver Injury Network developed cholestatic jaundice 2-12 weeks after starting ashwagandha; none had liver failure and liver tests normalized within 1-5 months where follow-up was available (Björnsson et al., 2020). An Indian series of eight single-ingredient cases was more serious: three patients with pre-existing chronic liver disease developed acute-on-chronic liver failure and died (Philips et al., 2023). Germany’s Federal Institute for Risk Assessment advises people with liver disease, pregnant and breastfeeding women, and children against ashwagandha supplements (BfR, 2024).

Ashwagandha may raise thyroid hormone levels. In a small 8-week RCT in 50 adults with subclinical hypothyroidism, 600 mg/day of root extract raised T3 and T4 and lowered TSH versus placebo (Sharma et al., 2018), and case reports describe thyrotoxicosis after use (Kamal et al., 2022). NCCIH advises caution for people with thyroid disorders and lists thyroid hormone medications among possible interactions (NCCIH). It should be avoided during pregnancy: safety data are lacking, and the herb has a history of traditional use as an abortifacient (BfR, 2024).

Rhodiola

Rhodiola extracts inhibit MAO in vitro, and a case report describes symptoms interpreted as serotonin syndrome in a woman taking rhodiola with paroxetine (Maniscalco et al., 2015), so combination with serotonergic antidepressants calls for caution. In a small study in healthy volunteers, 14 days of a commercial rhodiola product reduced CYP2C9 activity, which could matter for drugs cleared by that enzyme (Thu et al., 2016). The EMA limits traditional-use rhodiola medicines to adults over 18 and advises seeking medical advice if use continues beyond two weeks (EMA). Its activating profile may worsen insomnia or anxiety in some people if taken in the evening.

Panax Ginseng

Ginseng may weaken warfarin’s effect rather than strengthen it. A case report described a fall in INR after a patient on warfarin started ginseng (Janetzky and Morreale, 1997), and a 2004 randomized trial in 20 healthy volunteers (Annals of Internal Medicine) found that American ginseng lowered peak INR and warfarin levels versus placebo (Yuan et al., 2004); a small open-label trial of Panax ginseng in 25 stroke patients found no significant effect (Lee et al., 2008). Anyone on warfarin should have INR monitored if starting or stopping ginseng. Ginseng may also have additive glucose-lowering effects with antidiabetic medications, and case reports describe adverse reactions when it was combined with the MAO inhibitor phenelzine (Coon and Ernst, 2002).

Maca

Drug-interaction data for maca are scarce, so the absence of documented interactions is not evidence of safety. Glucosinolate content is a theoretical concern for individuals with thyroid conditions, though evidence for clinically significant thyroid effects at supplement doses is lacking.

Frequently Asked Questions

What are the benefits of adaptogens?

The benefits depend on the herb, not the label. Ashwagandha has the strongest trial data, for perceived stress and cortisol over 8 to 10 weeks. Rhodiola has moderate evidence for acute mental fatigue under cognitive load, and Panax ginseng limited-to-moderate evidence for cognition. Maca’s evidence is preliminary and mostly about libido. “Adaptogen” on its own promises nothing measurable.

What is the most powerful adaptogen?

No trial ranks adaptogens by strength, so “most powerful” has no evidence-based answer. Ashwagandha has the largest body of controlled trials, including a 64-person RCT in which serum cortisol fell 27.9% from baseline with a standardized root extract. That makes it the best-studied adaptogen, which is a different thing from the strongest one.

Which herbs count as adaptogens?

The herbs most often called adaptogens are ashwagandha, Rhodiola rosea and Panax ginseng, the three with the most human trial data. Maca and reishi are frequently marketed as adaptogens, but maca does not act on the HPA axis the way classic adaptogens are proposed to, and reishi’s research centers on immune effects. Stimulants such as caffeine fall outside the original definition.

Can you take multiple adaptogens together?

Combining adaptogens is common in commercial products, but no rigorous RCT has evaluated combination formulas against single-ingredient controls in matched populations. Without those comparisons, claims of synergy are not evidence-based. Stacking also complicates attribution if a side effect occurs. Starting with one adaptogen at a studied dose is the more cautious and interpretable approach.

How long does ashwagandha take to work?

Most RCTs have run 8 to 10 weeks at 300-600 mg daily; in the most-cited one, stress scores and serum cortisol were lower than with placebo at 60 days. (Chandrasekhar et al., PubMed, 2012). Individual response varies. Results from those trials may not carry over to products with unknown withanolide content.

Is rhodiola or ashwagandha better for stress?

They have different profiles. Rhodiola has better evidence for acute, short-term fatigue reduction under cognitive load. Ashwagandha has stronger evidence for chronic stress, cortisol reduction, and sleep quality over weeks of use. Selection depends on whether the target is acute mental performance or sustained HPA regulation. They are not interchangeable.

Does ginseng actually boost energy?

Evidence is mixed. Ginseng does not produce a stimulant effect comparable to caffeine. The best-supported energy application is fatigue reduction in clinical populations (cancer patients), not healthy-population endurance enhancement. (Barton et al., Journal of the National Cancer Institute, 2013). For healthy adults seeking performance enhancement, evidence is weak.

Are adaptogens safe during pregnancy?

No adaptogen reviewed here has adequate safety data from pregnancy trials. Ashwagandha is specifically advised against because pregnancy safety data are lacking and it has a history of traditional use as an abortifacient (BfR, 2024). Maca is a traditional food at lower doses but its safety as a supplement concentrate during pregnancy is unestablished. The conservative recommendation is to avoid adaptogen supplements during pregnancy and lactation unless supervised by a physician.

Conclusion

The adaptogen category is not monolithic. Ashwagandha sits at the top of the evidence hierarchy for chronic stress and cortisol management, with multiple RCTs, many using standardized KSM-66 extract, though overall certainty remains low. Rhodiola rosea has credible evidence for acute mental fatigue under stress. Panax ginseng has modest cognitive support data and a better-supported role in clinical fatigue than in healthy-population performance. Maca’s libido signal is consistent across small trials but preliminary, and it does not qualify as an HPA-axis adaptogen.

The practical implication: ignore marketing labels and match the compound’s evidence base to your specific goal. Verify standardization on every product. Maintain realistic expectations. None of these compounds replace sleep, exercise, nutrition, or stress management practices. They are, at best, useful adjuncts with a real but limited effect size.

Medical Disclaimer

The information in this article is for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any supplement, particularly if you take prescription medications, have a chronic health condition, or are pregnant or breastfeeding. The statements on this site have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.

References

Show all 36 referencesShow fewer

  1. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255-262. PubMed

  2. Shevtsov VA, Zholus BI, Shervarly VI, et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. 2003;10(2-3):95-105. PubMed

  3. Geng J, Dong J, Ni H, et al. Ginseng for cognition. Cochrane Database of Systematic Reviews. 2010;12:CD007769. PubMed

  4. Gonzales GF, Cordova A, Vega K, et al. Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia. 2002;34(6):367-72. PubMed

  5. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study. Cureus. 2019;11(9):e5797. PubMed

  6. Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals. 2010;3(1):188-224. PubMed

  7. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial. Journal of the National Cancer Institute. 2013;105(16):1230-8. PubMed

  8. Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). Journal of Alternative and Complementary Medicine. 2014;20(12):901-8. PubMed

  9. Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine. 2000;7(2):85-9. PubMed

  10. Hung SK, Perry R, Ernst E. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine. 2011;18(4):235-44. PubMed

  11. De Bock K, Eijnde BO, Ramaekers M, Hespel P. Acute Rhodiola rosea intake can improve endurance exercise performance. International Journal of Sport Nutrition and Exercise Metabolism. 2004;14(3):298-307. PubMed

  12. Kennedy DO, Scholey AB, Wesnes KA. Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutritional Neuroscience. 2001;4(4):295-310. PubMed

  13. Brooks NA, Wilcox G, Walker KZ, et al. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause. 2008;15(6):1157-62. PubMed

  14. Dording CM, Fisher L, Papakostas G, et al. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience & Therapeutics. 2008;14(3):182-91. PubMed

  15. Stone M, Ibarra A, Roller M, Zangara A, Stevenson E. A pilot investigation into the effect of maca supplementation on physical activity and sexual desire in sportsmen. Journal of Ethnopharmacology. 2009;126(3):574-6. PubMed

  16. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016;4:CD007731. PubMed

  17. Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver International. 2020;40(4):825-829. PubMed

  18. Philips CA, Valsan A, Theruvath AH, et al. Ashwagandha-induced liver injury: A case series from India and literature review. Hepatology Communications. 2023;7(10):e0270. PubMed

  19. Sharma AK, Basu I, Singh S. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. Journal of Alternative and Complementary Medicine. 2018;24(3):243-248. PubMed

  20. Kamal HI, Patel K, Brdak A, Heffernan J, Ahmad N. Ashwagandha as a unique cause of thyrotoxicosis presenting with supraventricular tachycardia. Cureus. 2022;14(3):e23494. PubMed

  21. German Federal Institute for Risk Assessment (BfR). Ashwagandha food supplements with potential health risks. Communication 39/2024. BfR

  22. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy. 1997;54(6):692-3. PubMed

  23. Yuan CS, Wei G, Dey L, et al. American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled trial. Annals of Internal Medicine. 2004;141(1):23-7. PubMed

  24. Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. Journal of Alternative and Complementary Medicine. 2008;14(6):715-21. PubMed

  25. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety. 2002;25(5):323-44. PubMed

  26. Darbinyan V, Aslanyan G, Amroyan E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nordic Journal of Psychiatry. 2007;61(5):343-8. PubMed

  27. Yang C, Li C, Wei W, et al. The unprecedented diversity of UGT94-family UDP-glycosyltransferases in Panax plants and their contribution to ginsenoside biosynthesis. Scientific Reports. 2020;10:15394. PubMed

  28. European Medicines Agency. Arctic root (Rhodiola rosea L., rhizoma et radix): summary for the public. EMA/HMPC/289537/2012. EMA

  29. Brekhman II, Dardymov IV. New substances of plant origin which increase nonspecific resistance. Annual Review of Pharmacology. 1969;9:419-30. PubMed

  30. Akhgarjand C, Asoudeh F, Bagheri A, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. 2022;36(11):4115-4124. PubMed

  31. Kaushik MK, Kaul SC, Wadhwa R, Yanagisawa M, Urade Y. Triethylene glycol, an active component of Ashwagandha (Withania somnifera) leaves, is responsible for sleep induction. PLoS One. 2017;12(2):e0172508. PubMed

  32. van Diermen D, Marston A, Bravo J, et al. Monoamine oxidase inhibition by Rhodiola rosea L. roots. Journal of Ethnopharmacology. 2009;122(2):397-401. PubMed

  33. Booker A, Jalil B, Frommenwiler D, et al. The authenticity and quality of Rhodiola rosea products. Phytomedicine. 2016;23(7):754-62. PubMed

  34. Wang HY, Qi LW, Wang CZ, Li P. Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides. American Journal of Chinese Medicine. 2011;39(6):1103-15. PubMed

  35. Maniscalco I, Toffol E, Giupponi G, Conca A. The interaction of Rhodiola rosea and antidepressants: a case report [in German]. Neuropsychiatrie. 2015;29(1):36-8. PubMed

  36. Thu OK, Spigset O, Nilsen OG, Hellum B. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. European Journal of Clinical Pharmacology. 2016;72(3):295-300. PubMed

Shopping for ashwagandha?

Top-ranked of 6 products compared.

  1. Best overallYoutheory Ashwagandha 1000 mg (KSM-66), 60 Count
    Check price on Amazon for Youtheory Ashwagandha 1000 mg (KSM-66), 60 Count (opens in a new tab)

Compare all 6 picks →Affiliate links. Disclosure.

Read next

Written by Superfoods Advisor Editors·Published July 4, 2026